Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||APC mutant|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|APC mutant||desmoid tumor||not applicable||N/A||Guideline||Diagnostic||APC mutations aid the diagnosis of desmoid tumor (NCCN.org).||detail...|
|APC mutant||small intestine adenocarcinoma||not applicable||N/A||Guideline||Risk Factor||Familial adenomatous polyposis results from germline mutations in the APC gene, and is associated with increased risk of developing small bowel adenocarcinoma (NCCN.org).||detail...|
|APC mutant||colorectal cancer||sensitive||JW74||Preclinical||Actionable||In a preclinical study, JW74 reduced tumor formation and growth in a mouse model of colorectal cancer harboring an APC mutation (PMID: 21199802).||21199802|
|APC mutant||colorectal cancer||no benefit||G-631||Preclinical - Cell line xenograft||Actionable||In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561).||26692561|
|APC mutant||colon adenoma||predicted - sensitive||TetMYB||Preclinical||Actionable||In a preclinical study, TetMYB treatment resulted in improved median survival compared to control (356 vs 183 days) in APC-driven mouse models of colon adenoma (Gastroenterology, Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269).||detail...|
|APC mutant||medulloblastoma||not applicable||N/A||Guideline||Prognostic||WNT-driven medulloblastomas, characterized by CTNNB1 or APC mutations, are associated with favorable prognosis (NCCN.org).||detail...|
|APC mutant||colorectal cancer||predicted - sensitive||K-756||Preclinical||Actionable||In a preclinical study, K-756 inhibited Wnt signaling and reduced growth of 2/3 tested APC-mutant colorectal cancer cell lines in culture (PMID: 27196752).||27196752|